Program Overview
This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will highlight strategies to identify and manage spasticity in patients with multiple sclerosis (MS). The expert faculty, Dr. Fred D. Lublin, will first review the unmet needs of multiple sclerosis patients with spasticity. Next, an analysis of current and emerging clinical trial data for cannabinoid therapeutics will be discussed. Following, Dr. Lublin will examine how to develop strategies and technologies for live and virtual patient care to manage spasticity and related symptoms for patients with MS.
Target Audience
Neurologists, MS specialists, and physicians’ assistants who comprise the comprehensive MS care team, as well as other healthcare professionals involved in the management of patients with multiple sclerosis
Agenda
I. Identification and Unmet Needs of MS Patients with Spasticity and Related Symptoms
II. Clinical Trial Data Analysis for Cannabinoid Therapeutics to Improve Outcomes in MS Patients with Spasticity
III. Strategies and Technologies for Live and Virtual Patient Care to Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis
Learning Objectives
- Review the identification and unmet needs of MS patients with spasticity and related symptoms.
- Analyze clinical trial data for cannabinoid therapeutics to improve outcomes in MS patients with spasticity.
- Develop strategies and technologies for live and virtual patient care to manage spasticity and related symptoms in patients with multiple sclerosis.
Faculty
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Fred D. Lublin, MD | Consultant/Advisor: Biogen; EMD Serono; Novartis; Teva; Actelion/Janssen; Sanofi/Genzyme; Acorda; Roche/Genentech; MedImmune/Viela Bio/Horizon Therapeutics; Receptos/Celgene/BMS; TG Therapeutics; Medday; Atara Biotherapeutics; Mapi Pharma; Apitope; Orion Biotechnology; Brainstorm Cell Therapeutics; Jazz Pharmaceuticals; GW Pharma; Mylan; Immunic; Population Council; Avotres; Neurogene; Banner Life Sciences; Labcorp; Entelexo Biotherapeutics; Neuralight; SetPoint Medical
Grant/Research Support: Novartis; Actelion; Biogen; Sanofi, NMSS, NIH; Brainstorm Cell Therapeutics |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Financial Support
This activity has been supported by an independent educational grant from Jazz Pharmaceuticals
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Jazz Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
